Disease Activity Score and Disease Pathway Scores Measured Using the Multiple Sclerosis Disease Activity Test are Significantly Reduced Prior to the Week 96 Dose for Patients Treated with Ublituximab in the Phase 3 ULTIMATE I and II Studies

site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
Drug Category: Array
Conference Category: Array
Lead Author: Foley J, et al.
Published Date: 12/10/2023
Download Link: /wp-content/uploads/2023/10/Foley-MSMilan-2023-Disease-Activity-Score-and-Disease-Pathway.pdf
Download Text:
Popup Confirmation?:
astra-migrate-meta-layouts: set
Scroll to Top